Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Sponsors
Hebei Yiling Hospital, Renmin Hospital of Wuhan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia; 2. Above 18 years old (inclusive); 3. At the time of enrollment, the patient had any of the main symptoms (fever, cough, fatigue); 4. Voluntarily sign written informed consent.
Exclusion criteria
Exclusion criteria: 1. There is clear evidence of bacterial infection in respiratory tract infections caused by basic diseases such as primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformations, congenital heart disease, gastroesophageal reflux disease, and abnormal lung development; 2. Subjects with the following conditions: asthma requiring daily treatment, any other chronic respiratory disease, respiratory bacterial infections such as purulent tonsillitis, acute tracheobronchitis, sinusitis, otitis media, and other respiratory tracts diseases that affecting clinical trial evaluation . Chest CT confirmed that patients with basic pulmonary diseases such as severe pulmonary interstitial lesions and bronchiectasis; 3. Severe pneumonia requires mechanical ventilation; 4. In the opinion of the investigator, previous or present illnesses may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc .; 5. Pregnant or lactating women; 6. Patients who participated in other clinical trials within the last 3 months; 7. An allergic condition, such as a history of allergies to two or more drugs or foods, or a known allergy to the ingredients of the drug; 8. The investigator believes that there are any factors that are not suitable for enrollment or affect the evaluation of the efficacy.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Disease recovery rate;Rate of CT improvement;Proportion of aggravation during treatment (in line with the definition of severe or critical illness in the treatment scheme);Time and rate of coronavirus become negative;Single symptom disappearance rate and main symptom disappearance time;Routine blood test;Biochemical Indicators; | — |
Primary
| Measure | Time frame |
|---|---|
| Clinical symptoms (fever, weakness, cough) recovery rate and recovery time; | — |
Countries
China
Contacts
Public ContactJia Zhenhua/Zhong Nanshan
Hebei Yiling Hospital /The First Affiliated Hospital of Guangzhou Medical University
Outcome results
None listed